ocrelizumab
onartuzumab
iratumumab
atezolizumab
Ab
vobarilizumab
monoantibody
agonistic monoclonal antibody
serospecific
soravtansine
-mab
sibrotuzumab
teplizumab
dorlixizumab
bococizumab
naptumomab estafenatox
carlumab
mapatumumab
guselkumab
dalotuzumab
lexatumumab
antidesmoglein
drozitumab
evolocumab
anticorrelate
thrombophylactic
zanolimumab
autocentromere
antipolyvalent
robatumumab
adecatumumab
ipilimumab
milatuzumab
immunoglobin
siltuximab
antiserum
cergutuzumab
figitumumab
dacetuzumab
elotuzumab
sonepcizumab
thrombocythemia
tucotuzumab
antisubstance
teprotumumab
thrombosuppressive
bavituximab
pamrevlumab
antiphosphospecific
seroblock